Mesenchymal stromal cells with chimeric antigen receptors for enhanced immunosuppression
Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
In a collaborative effort between 18 centers, researchers have developed a system that effectively stratifies children at the onset of acute graft versus host disease for risk of non-relapse mortality over 6 months.
Nivolumab/Ipilimumab Plus RT Shows Promise in Locally Advanced Rectal Cancer
The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.
EU’s CHMP Recommends Odronextamab Approval in Follicular Lymphoma, DLBCL
Findings from ELM-1 and ELM-2 support the positive opinion for odronextamab as a treatment for relapsed/refractory follicular lymphoma and DLBCL.
Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
ASCO Updates Guidelines for CDK4/6 Inhibitor Use in Breast Cancer
The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
Lunresertib Combo Shows Responses in Advanced Pretreated GI Cancer Subtypes
Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
Ivonescimab/Chemotherapy Improves PFS in EGFR TKI–Treated NSCLC
The first-in-class tetravalent bispecific antibody may show binding affinity to PD1 and VEGF based on in vitro studies.
Bispecific Antibodies are Helping to Advance the Field of Lymphoma
Julie M. Vose, MD, MBA, and Avyakta Kallam, MD, highlighted research advances in the lymphoma field they’ve witnessed throughout their careers.
EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma
The European Commission is expected to decide on approving epcoritamab in relapsed/refractory follicular lymphoma later in 2024.
Nivolumab Combo Improves HRQOL Vs Chemo in MSI-H/dMMR Metastatic CRC
HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.
FDA Approves Novel Formulation for Breast and Ovarian Cancers
A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.
Acalabrutnib Combo Shows PFS Benefit in Elderly MCL Population
Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.
CAR T-Cell Therapy Demonstrates Promising Results for mCRPC
In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.
FDA Sends CRL for Patritumab Deruxtecan in Advanced EGFR+ NSCLC
The complete response letter for patritumab deruxtecan is based on findings related to a third-party manufacturing site inspection.
Younger Age Improves Pregnancy Prospects After ET Therapy Pause in HR+ Breast Cancer
Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.
FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma
Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
Osimertinib/Chemotherapy Attains Japanese Approval in EGFR+ Advanced NSCLC
The approval for osimertinib/chemotherapy by the Japanese Pharmaceuticals and Medical Device Agency was based on results from the phase 3 FLAURA2 trial.
Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Mitazalimab/Chemo Prolongs Survival, Responses in Pancreatic Cancer
More than half of the patients who received mitazalimab plus chemotherapy experienced an unconfirmed objective response in the phase 2 OPTIMIZE-1 study.
Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Durvalumab Shows Improvement in EFS/OS for Muscle-Invasive Bladder Cancer
Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.
American Society for Radiation Oncology Names Vivek S. Kavadi as CEO
Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.
FDA Places Partial Holds on 3 Trials for Solid Tumor Treatment, Azenosertib
Two deaths due to presumed sepsis in patients treated in the DENALI trial led to the clinical holds on the advanced solid tumor treatment.
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
Perioperative Modified FOLFIRINOX Shows Encouraging Outcomes in Pancreatic Cancer
Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.
Momelotinib Receives Japanese Approval for Treatment of Myelofibrosis
Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.
European Commission Approves Fruquintinib in Pretreated Metastatic CRC
Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.